Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Cash & Equivalents (2016 - 2025)

Acro Biomedical has reported Cash & Equivalents over the past 10 years, most recently at $4098.0 for Q4 2025.

  • Quarterly results put Cash & Equivalents at $4098.0 for Q4 2025, up 760.92% from a year ago — trailing twelve months through Dec 2025 was $4098.0 (up 760.92% YoY), and the annual figure for FY2025 was $4098.0, up 760.92%.
  • Cash & Equivalents for Q4 2025 was $4098.0 at Acro Biomedical, down from $4323.0 in the prior quarter.
  • Over the last five years, Cash & Equivalents for ACBM hit a ceiling of $357668.0 in Q1 2022 and a floor of $26.0 in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $3684.5 (2023), compared with a mean of $44959.0.
  • Biggest five-year swings in Cash & Equivalents: soared 99042.95% in 2021 and later crashed 99.91% in 2023.
  • Acro Biomedical's Cash & Equivalents stood at $95248.0 in 2021, then tumbled by 93.86% to $5852.0 in 2022, then tumbled by 93.57% to $376.0 in 2023, then rose by 26.6% to $476.0 in 2024, then soared by 760.92% to $4098.0 in 2025.
  • The last three reported values for Cash & Equivalents were $4098.0 (Q4 2025), $4323.0 (Q3 2025), and $26.0 (Q2 2025) per Business Quant data.